# Neuland Laboratories (NSE: NEULANDLAB) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/NEULANDLAB · Pivot · prices to 21 Oct 2026

Neuland Laboratories (NSE: NEULANDLAB) closed at ₹18,740.00 on 21 Oct 2026, down 2.57% on the day. With a market capitalisation of ₹24,050 Cr, it ranks 316th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 65.9× trailing earnings, against a return on equity of 19.4% in FY26. Over the past year the share price has risen 15.6%. Its 52-week range is ₹11,500.00 (23 Mar 2026) to ₹24,225.00 (9 Sep 2026); the last close is 22.6% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹642 Cr (+119.2% year on year) and net profit ₹148 Cr (+962.4%), on a consolidated basis. Promoters held 32.62% of the company as of 30 Jun 2026; 2.29% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹18,740.00 |
| Market cap | ₹24,050 Cr |
| P/E (trailing) | 65.9 |
| ROE | 19.4% (FY26) |
| ROCE | 23.1% (FY26) |
| Debt to equity | 0.1 |
| 52-week high | ₹24,225.00 (9 Sep 2026) |
| 52-week low | ₹11,500.00 (23 Mar 2026) |
| 1-year return | +15.6% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹642 Cr | +119.2% | ₹148 Cr | +962.4% | ₹115.10 |
| Q4 FY26 | ₹776 Cr | +136.4% | ₹213 Cr | +664.7% | ₹165.76 |
| Q3 FY26 | ₹440 Cr | +10.5% | ₹41 Cr | −60.1% | ₹31.62 |
| Q2 FY26 | ₹514 Cr | +65.4% | ₹97 Cr | +194.9% | ₹75.49 |
| Q1 FY26 | ₹293 Cr | −33.4% | ₹14 Cr | −85.8% | ₹10.83 |
| Q4 FY25 | ₹328 Cr | −14.7% | ₹28 Cr | −58.8% | ₹21.67 |
| Q3 FY25 | ₹398 Cr | +1.3% | ₹102 Cr | +24.8% | ₹79.18 |
| Q2 FY25 | ₹311 Cr | −25.6% | ₹33 Cr | −63.2% | ₹25.60 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,477 Cr | ₹260 Cr |
| FY24 | ₹1,559 Cr | ₹300 Cr |
| FY23 | ₹1,191 Cr | ₹164 Cr |
| FY22 | ₹951 Cr | ₹64 Cr |
| FY21 | ₹937 Cr | ₹81 Cr |
| FY20 | ₹763 Cr | ₹16 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 32.62%
- Foreign institutions: 21.08%
- Domestic institutions: 16.51%
- Non-institutions: 29.79%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Krishna Institute of Medical Sciences](https://app.pivotnow.in/stock/KIMS) | ₹672.75 | ₹28,256 Cr | 112.1 | 18.0% |
| [Piramal Pharma](https://app.pivotnow.in/stock/PPLPHARMA) | ₹198.24 | ₹26,393 Cr | 25 | −4.0% |
| [Rubicon Research](https://app.pivotnow.in/stock/RUBICON) | ₹1,433.20 | ₹23,703 Cr | 93.9 | 19.1% |
| [Procter Gamble](https://app.pivotnow.in/stock/PGHH) | ₹7,006.50 | ₹22,744 Cr | 26.5 | 62.3% |
| [Piramal Phytoca](https://app.pivotnow.in/stock/PIRPHYTO) | — | ₹21,083 Cr | — | — |
| [SAGILITY](https://app.pivotnow.in/stock/SAGILITY) | ₹43.69 | ₹20,453 Cr | 22.1 | 9.6% |

## Questions and answers

### What is the share price of Neuland Laboratories today?

Neuland Laboratories (NSE: NEULANDLAB) last closed at ₹18,740.00 on 21 Oct 2026. Its 52-week high is ₹24,225.00 and its 52-week low is ₹11,500.00.

### What is the market cap of Neuland Laboratories?

Neuland Laboratories' market capitalisation is ₹24,050 Cr (₹24,050 Cr) at the 21 Oct 2026 close, ranking 316th among the NSE companies Pivot tracks.

### What is the P/E ratio of Neuland Laboratories?

Neuland Laboratories trades at a trailing P/E of 65.9. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 26.5.

### What is the ROE and ROCE of Neuland Laboratories?

Return on equity was 19.4% in FY26 and return on capital employed was 23.1% in FY26 (consolidated figures).

### Is Neuland Laboratories a debt-free company?

No. Neuland Laboratories' debt-to-equity ratio was 0.1 in FY26, with total debt of ₹161 Cr.

### What were Neuland Laboratories' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Neuland Laboratories reported revenue of ₹642 Cr, +119.2% year on year, and net profit of ₹148 Cr, +962.4% year on year.

### How has Neuland Laboratories stock performed over the last year?

Neuland Laboratories' share price has risen 15.6% over the past year, −0.7% over three months and −17.4% over one month, to the 21 Oct 2026 close.

### What is the shareholding pattern of Neuland Laboratories?

As of 30 Jun 2026: promoters 32.62%, foreign institutions 21.08%, domestic institutions 16.51%, non-institutions 29.79%. 2.29% of promoter shares were pledged.

### Who are Neuland Laboratories' competitors?

The listed Pharma & Healthcare companies closest to Neuland Laboratories by market cap are Krishna Institute of Medical Sciences, Piramal Pharma, Rubicon Research, Procter Gamble, Piramal Phytoca and SAGILITY.

### Is Neuland Laboratories a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Neuland Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NEULANDLAB against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.